Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 15 clinical trials
Validation of the Second Generation of the Controlled Attenuation Parameter (CAP) Using the MRI-PDFF as Reference

proton density fat fraction (MRI-PDFF) which has shown at least equivalence in accuracy for quantifying hepatic steatosis with both 1H Magnetic Resonance Spectroscopy and with histological grade, across

vibration controlled transient elastography
shear wave elastography
  • 30 Aug, 2021
  • 8 locations
Lifestyle Modification for MAFLD Based on TTM

Lifestyle changes aiming at weight loss remain the cornerstone of MAFLD treatment.Evaluating the motivational stage of patients' change and providing targeted lifestyle guidance may significantly improve the efficiency of weight loss. The investigators hypothesize that gut microbiota may affect motivation to lose weight, and the changes in gut microbiota due …

  • 13 May, 2021
  • 1 location
Follow-up of NAFLD Patients With MRI-PDFF

The liver is a key organ in metabolism and contributes to T2DM development and insulin resistance via unclear mechanisms that may involve liver fat accumulation, inflammatory signals, and immune cells are proposed to play an important role in the pathogenesis of both NAFLD and T2DM.

  • 16 Aug, 2021
  • 1 location
The Sonic Incytes Liver Incytes System Evaluation of Liver Fibrosis and Steatosis Versus MRE and MRI PDFF

The main purpose of this study is to compare the effectiveness of various non-invasive elastography techniques at determining liver stiffness measures in human subjects. Specifically, the investigators are comparing MRE and FibroScan to Vibroelastography (VE, Liver Incytes System). These techniques are used to measure stiffness in the liver.

  • 27 Jan, 2021
Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

without DM has not been investigated. Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) and liver stiffness measurement (LSM) are non-invasive methods to diagnose hepatic steatosis

  • 06 May, 2021
  • 1 location
A Study to Assess the Safety Efficacy and Pharmacokinetics of Multiple Doses of ION224

steatohepatitis (NASH) histologic improvement and to assess the effect on liver steatosis by magnetic resonance imaging-determined proton density fat fraction (MRI-PDFF), additional changes in NASH histologic

  • 22 Sep, 2021
  • 22 locations
Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)

This study will assess the effect of 3 doses of PXL065 versus placebo on liver fat content in NASH patients after 36 weeks of treatment

  • 28 Jan, 2021
  • 1 location
A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH

The main objective of this study is to evaluate safety and efficacy of ALS-L1023 in patients with Non-alcoholic steatohepatitis

fatty liver
  • 01 Feb, 2021
  • 1 location
Saroglitazar Magnesium 4 mg in the Treatment of NAFLD in Women With PCOS (EVIDENCES VII)

This is a multicenter, phase 2A, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of Saroglitazar Magnesium in women with well characterized PCOS.

  • 29 Jan, 2021
  • 24 locations
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis

This is an open-label, randomized study comparing a monitored ketogenic diet intervention using standard ketogenic diet (SKD) and standard of care (SOC) dietary recommendations for 16 weeks. Subjects enrolled in the standard of care group will receive a voucher to Weight Watchers after study completion.

fatty liver
  • 25 Jan, 2021
  • 1 location